JINYU(SH:600201) Sou Hu Cai Jing·2025-12-23 15:50Core Viewpoint - The controlling shareholder of Inner Mongolia Biological Co., Ltd. plans to increase its stake in the company by no less than RMB 50 million and no more than RMB 100 million within the next 12 months, without setting a fixed price or price range, demonstrating confidence in the company's long-term intrinsic value and a commitment to face market fluctuations together with all shareholders [1]. Group 1 - The announcement of the share buyback plan reflects the culmination of years of efforts to resolve governance issues within the company [1]. - The previous failed fundraising attempt in 2022 due to pricing disputes highlighted the challenges posed by a dispersed shareholding structure, which ultimately led to a governance transformation [2]. - The successful implementation of a new fundraising plan in 2024, with a share price of RMB 14.25, marked a 113% increase from the previously rejected price of RMB 6.69, establishing a new value benchmark for the company [2]. Group 2 - The strategic evolution from a failed low-price fundraising attempt in 2022 to a successful high-price issuance in 2024, followed by an unlimited market buyback in 2025, illustrates a clear strategic loop for the company [3]. - The controlling shareholder's decision to conduct an unconditional buyback without a price range signifies a shift towards long-term value creation based on solid governance [3].